Remove 2023 Remove Equities Remove Private Equity
article thumbnail

2024 Healthcare Private Equity Outlook & Trends

JD Supra: Mergers

W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity. As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector.

article thumbnail

The Road Ahead for Private Equity: Reflections and Predictions

JD Supra: Mergers

The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Although overall transaction volume was significantly down, private equity funds still found. By: Akin Gump Strauss Hauer & Feld LLP

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Healthcare & Life Sciences Private Equity Deal Tracker: WindRose Acquires CardioOne 

JD Supra: Mergers

CardioOne, founded in 2023 and based in Houston, is a management services partner and technology platform designed for independent cardiology practices. WindRose Health Investors has announced its acquisition of CardioOne. By: McGuireWoods LLP

article thumbnail

Healthcare Private Equity Transactions Under Scrutiny: Mid-Year Review

JD Supra: Mergers

At the end of last year, Holland & Knight predicted that "the current enforcement environment will continue into 2024 and will focus heavily on the healthcare industry, along with private equity transactions or 'roll-ups.' 15, 2023.) As the summer. By: Holland & Knight LLP

article thumbnail

Looking Ahead to 2025: Private Equity Risk and Insurance Trends

JD Supra: Mergers

In last year’s Looking Ahead Guide, we had predicted the 2024 deal landscape would improve over 2023 year-end results in terms of number of closed buyout transactions, transaction values, and exits. This seems to be the case, as we see initial signs of an improving landscape after a stronger Q2.

article thumbnail

Court Dismisses “Roll-Up” Lawsuit against Private Equity Firm in Blow to FTC

JD Supra: Mergers

On May 13, a federal district court in Texas dismissed private equity firm Welsh, Carson, Anderson & Stowe (Welsh Carson) from an antitrust lawsuit filed by the Federal Trade Commission (FTC). The lawsuit, which was originally filed in 2023, alleged that Welsh Carson and co-defendant U.S. Anesthesia Partners, Inc.

article thumbnail

FTC Sues Private Equity Firm, Portfolio Company Over Anesthesiology Roll-Up Strategy

JD Supra: Mergers

21, 2023, sued a private equity firm in the U.S. The Federal Trade Commission (FTC) on Sept. District Court for the Southern District of Texas over an alleged decade-long "roll-up" strategy to consolidate anesthesiology practices in Texas. By: Holland & Knight LLP